News / Taiwan / economic_daily
US Healthcare Stocks Rally on Democratic Election Gains, Boosting Taiwan Biotech Sector
Health Technology · Biotechnology · economic_daily · 2026-11-05
1786, 1795, 6446, 6472, 6782, 6919, 6949
US healthcare stocks surged on expectations of favorable policy continuity following Democratic election gains, fueling a rally in Taiwan's biotech sector, led by strong earnings and new product approvals from companies like Bora Pharmaceuticals.
What Happened
Policy-Driven Rally: US healthcare and insurance stocks rallied as investors anticipated that Democratic control of Congress would prevent cuts to Medicaid and potentially restore ACA subsidies. Analysts noted that the current political landscape reduces the likelihood of immediate, drastic changes to drug pricing policies, providing stability for major pharmaceutical firms.
Taiwan Biotech Momentum: The positive sentiment in the US spilled over into the Taiwan stock market, where biotech firms like SciVision Biotech and KangPei saw significant gains. Investors flocked to the sector, pushing several key players higher as the market reacted to the favorable regulatory outlook in the United States.
Bora Pharmaceuticals Performance: Bora Pharmaceuticals reported a record-breaking September consolidated revenue of NT$2.33 billion, a 35.13% year-over-year increase. Despite routine maintenance at its Maryland facility, the company maintained strong output through its Canadian and Zhunan plants, effectively managing its robust order backlog.
Positive Outlook: Looking ahead to the fourth quarter, Bora expects continued growth driven by seasonal demand in the pharmaceutical and retail sectors. The company also expanded its ophthalmology portfolio with a new drug approval for its US subsidiary, Upsher-Smith, while its Weider health supplement business prepares for peak retail promotional activity.